We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-3.29%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.59B
AUM Growth
+$431M
Cap. Flow
+$681M
Cap. Flow %
26.3%
Top 10 Hldgs %
45.87%
Holding
70
New
15
Increased
18
Reduced
13
Closed
7

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$89.7M
2
NVCR icon
NovoCure
NVCR
+$72.1M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$61.3M
4
AXSM icon
Axsome Therapeutics
AXSM
+$56.6M
5
APGE icon
Apogee Therapeutics
APGE
+$53.2M

Top Sells

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$59.3M
2
GPCR icon
Structure Therapeutics
GPCR
+$23.6M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$14.9M
4
INSM icon
Insmed
INSM
+$11.4M
5
INZY
Inozyme Pharma
INZY
+$9.16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$22.3B
$152M 5.85%
6,000,000
-500,000
-8% -$11.4M
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$16B
$147M 5.69%
1,138,045
-111,955
-9% -$14.9M
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$135M 5.23%
2,600,000
+1,051,748
+68% +$61.3M
IONS icon
4
Ionis Pharmaceuticals
IONS
$8.95B
$129M 4.96%
2,834,069
– –
GH icon
5
Guardant Health
GH
$19.1B
$120M 4.63%
4,050,000
+2,550,000
+170% +$89.7M
IMVT icon
6
Immunovant
IMVT
$7.98B
$107M 4.15%
2,797,955
-2,623,375
-48% -$59.3M
ALKS icon
7
Alkermes
ALKS
$8.08B
$106M 4.11%
3,800,000
+800,000
+27% +$23.5M
DVAX
8
DELISTED
Dynavax Technologies
DVAX
$99.8M 3.85%
6,756,956
+199,140
+3% +$2.8M
GPCR icon
9
Structure Therapeutics
GPCR
$3.35B
$96.6M 3.73%
1,915,000
-731,782
-28% -$23.6M
PLRX icon
10
Pliant Therapeutics
PLRX
$65M
$95.4M 3.68%
5,500,000
+1,450,000
+36% +$25.1M
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
$82M 3.16%
3,546,435
– –
AXSM icon
12
Axsome Therapeutics
AXSM
$11.8B
$79.7M 3.08%
1,140,745
+756,545
+197% +$56.6M
BCYC
13
Bicycle Therapeutics
BCYC
$271M
$70.1M 2.71%
3,490,506
+671,461
+24% +$15.4M
TVTX icon
14
Travere Therapeutics
TVTX
$5.18B
$65.9M 2.54%
7,370,000
– –
NTLA icon
15
Intellia Therapeutics
NTLA
$1.51B
$63.2M 2.44%
2,000,000
+1,164,554
+139% +$45.2M
EDIT icon
16
Editas Medicine
EDIT
$396M
$55.4M 2.14%
7,101,935
+3,648,191
+106% +$31.3M
GERN icon
17
Geron
GERN
$905M
$54.5M 2.1%
25,700,000
+1,529,034
+6% +$4.15M
VRNA
18
DELISTED
Verona Pharma
VRNA
$52M 2.01%
3,187,415
– –
APGE icon
19
Apogee Therapeutics
APGE
$10.1B
$51.4M 1.98%
+2,414,373
New +$53.2M
PACB icon
20
Pacific Biosciences
PACB
$435M
$50.1M 1.93%
6,000,000
+4,548,799
+313% +$52M
VRDN icon
21
Viridian Therapeutics
VRDN
$2.18B
$45.5M 1.75%
2,963,267
+1,683,765
+132% +$32.1M
NVCR icon
22
NovoCure
NVCR
$1.75B
$40.4M 1.56%
+2,500,000
New +$72.1M
HLVX
23
DELISTED
HilleVax
HLVX
$39M 1.51%
+2,900,000
New +$40.8M
RPTX
24
DELISTED
Repare Therapeutics
RPTX
$37.1M 1.43%
3,067,731
+340,125
+12% +$3.51M
AGEN
25
Agenus
AGEN
$280M
$35.8M 1.38%
1,584,877
+84,877
+6% +$2.41M
1
2 3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Deep Track Capital held 70 positions worth $2.59B, up 20% from $2.16B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Deep Track Capital deployed $681M of net new capital in Q3 2023, opening 15 new positions and adding to 18 existing holdings. Its largest new stake was NovoCure: 2,500,000 shares worth $40.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Immunovant, an estimated $59.3M trimmed.

  • Deep Track Capital's largest Q3 2023 buy was NovoCure: 2,500,000 shares worth $40.4M.
  • Deep Track Capital added most to Guardant Health in Q3 2023, an estimated $89.7M increase.
  • Deep Track Capital's biggest Q3 2023 reduction was Immunovant, cutting an estimated $59.3M.
  • Deep Track Capital fully exited Inozyme Pharma in Q3 2023, selling an estimated $9.16M.
  • Deep Track Capital's ten largest holdings make up 46% of its $2.59B portfolio in Q3 2023.
  • Deep Track Capital opened 15 new positions and closed 7 in Q3 2023.
  • Deep Track Capital's portfolio value rose 20% quarter-over-quarter to $2.59B.

Based on Deep Track Capital's 13F filing for Q3 2023, filed 14 Nov 2023.